动物造模,肺缺血再灌注损伤 Z-bio 2022-12-19 303

　　Objective To investigate the effect of dexmedetomidine combined with sufentanil on lung ischemia-reperfusion injury (LIRI) in rats.

　　Methods SD rats were randomly divided into sham operation group, model group, sufentanil treatment group, dexmedetomidine treatment group and sufentanil+dexmedetomidine treatment group. Except the sham operation group, the other four groups of rats were given 20 μ G/kg sufentanil, 25.2 μ G/kg dexmedetomidine and 20 μ G/kg sufentanil+25. 2 μ G/kg dexmedetomidine, and then LIRI model was established. After the test, the lung tissue structure was observed by HE staining and TUNEL staining, the mitochondrial damage of lung cells was observed by electron microscopy, the levels of SOD and MDA in lung tissue were detected by ELISA, and the levels of LC3B, Beclin1, ATG5, HO-1 and Nrf-2 proteins in lung tissue were detected by Western blot.

　　Results 20 μ G/kg sufentanil and 25.2 μ G/kg dexmedetomidine and its combination improved lung tissue injury in LIRI rats, reduced apoptosis of lung cells, reduced mitochondrial swelling of lung cells, and reduced the expression of SOD and MDA. In addition, it also reduced the expression of LC3B - Ⅱ, Beclin1, ATG5 proteins, LC3B - Ⅱ/LC3B - Ⅰ ratio, and increased the expression of LC3B - Ⅰ, Nrf-2, and HO-1 proteins, of which 20 μ G/kg sufentanil compound 25.2 μ Dextrmedetomidine g/kg was the best in the three treatment groups.

　　Conclusion Dextrmedetomidine, sufentanil and their combination can effectively protect LIRI in rats. Dextrmedetomidine and sufentanil have a synergistic effect on improving LIRI in rats. The mechanism may be related to the activation of Nrf-2/HO-1 antioxidant stress pathway and the inhibition of excessive autophagy.